The estimated Net Worth of Gail Cawkwell is at least $2.46 Milión dollars as of 1 July 2023. Gail Cawkwell owns over 15,000 units of Intercept Pharmaceuticals Inc stock worth over $285,000 and over the last 6 years he sold ICPT stock worth over $0. In addition, he makes $2,174,700 as Senior Vice President - Medical Affairs a Safety & Pharmacovigilance at Intercept Pharmaceuticals Inc.
Sign up
Gail Cawkwell ICPT stock SEC Form 4 insiders trading
Gail has made over 5 trades of the Intercept Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ICPT stock worth $285,000 on 1 July 2023.
The largest trade he's ever made was exercising 15,000 units of Intercept Pharmaceuticals Inc stock on 1 July 2023 worth over $285,000. On average, Gail trades about 659 units every 59 days since 2019. As of 1 July 2023 he still owns at least 15,000 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Gail Cawkwell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gail Cawkwell biography
Dr. Gail Cawkwell serves as Senior Vice President - Medical Affairs, Safety & Pharmacovigilance of the Company. Prior to joining the Company, Dr. Cawkwell worked for Purdue Pharma L.P., where she served as Special Advisor to the Board of Directors from September 2017 to February 2018, Chief Medical Officer from January 2015 to September 2017 and VP, Medical Affairs from November 2014 to January 2015. From 2000 to November 2014, Dr. Cawkwell served in a number of roles of increasing responsibility at Pfizer Inc., including most recently as Vice President Medicine Team Lead for Pfizer’s tofacitinib franchise. Dr. Cawkwell also served as a Clinical Instructor of Pediatrics at Columbia Presbyterian Health Center from 2002 to 2015 and previously held several other clinical and academic posts. Dr. Cawkwell received her Ph.D. from the University of Cincinnati, her M.D. from McGill University in Montreal, Canada and her bachelor’s degree from Duke University.
What is the salary of Gail Cawkwell?
As the Senior Vice President - Medical Affairs a Safety & Pharmacovigilance of Intercept Pharmaceuticals Inc, the total compensation of Gail Cawkwell at Intercept Pharmaceuticals Inc is $2,174,700. There are 5 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.
How old is Gail Cawkwell?
Gail Cawkwell is 58, he's been the Senior Vice President - Medical Affairs a Safety & Pharmacovigilance of Intercept Pharmaceuticals Inc since 2018. There are 6 older and 18 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
What's Gail Cawkwell's mailing address?
Gail's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE, PA, 19087.
Insiders trading at Intercept Pharmaceuticals Inc
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein a Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
What does Intercept Pharmaceuticals Inc's logo look like?
Complete history of Gail Cawkwell stock trades at Aclaris Therapeutics Inc a Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc executives and stock owners
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Mark Pruzanski,
President, Chief Executive Officer, Director -
Jerome Durso,
Chief Operating Officer -
Ryan Sullivan,
General Counsel, Secretary -
Richard Kim,
President, U.S. Commercial & Strategic Marketing -
Sandip Kapadia,
Chief Financial Officer, Treasurer -
Gail Cawkwell,
Senior Vice President - Medical Affairs, Safety & Pharmacovigilance -
Lisa Bright,
President, International -
David Ford,
Chief Human Resource Officer -
Dr. Mark Pruzanski M.D.,
Founder, Advisor & Director -
Jerome B. Durso,
Pres, CEO & Director -
Paolo Fundaro,
Independent Chairman of the Board -
Gino Santini,
Lead Independent Director -
Glenn Sblendorio,
Independent Director -
Daniel Welch,
Independent Director -
Daniel Bradbury,
Independent Director -
Luca Benatti,
Independent Director -
Nancy Miller-Rich,
Independent Director -
Keith Gottesdiener,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Jason Campagna,
Chief Medical Officer -
Christian Weyer,
Executive Vice President - Research & Development -
Linda M. Richardson,
Exec. VP & Chief Commercial Officer -
Jared M. Freedberg J.D.,
Gen. Counsel -
Lisa M. DeFrancesco,
Sr. VP of Corp. Affairs & Investor Relations -
Rocco Venezia,
Chief Accounting Officer & Treasurer -
Bryan Ball,
Chief Quality Officer & Sr. VP of Operations -
Andrew Saik,
Chief Financial Officer -
Barbara Gayle Duncan,
Chief Financial Officer -
Rachel Mc Minn,
Chief Strategy Officer -
David Shapiro,
Chief Medical Officer -
Linda M Richardson,
EVP & Chief Commercial Officer -
S.P.A. Genextra,
-
M Michelle Berrey,
President, R&D and CMO -
Daniel Paul Regan,
Chief Commerical Officer -
Jonathan Silverstein,
Director -
Advisors Llc Orbi Med Capit...,
-
Lorenzo Tallarigo,
Director -
Klaus R Dr Veitinger,
Director -
Sanj K Patel,
Director -
Luciano Adorini,
Chief Scientific Officer -
Nicole Williams,
Director -
Francesco Micheli,
-
Bryan Ball,
Chief Qual. Officer & SVP Ops. -
Rocco Venezia,
Chief Accounting Officer -
Dagmar Rosa Bjorkeson,
Director -
Lisa De Francesco,
SVP, IR & Corp. Affairs -
Jared Freedberg,
General Counsel